SINAT ALEJE: Open Payments
NPI 1609496736 · LOS ANGELES, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,165 in 22 payments from 8 companies in 2025. Trend: 2023 $823 · 2024 $505 · 2025 $1,165
Food & beverage: $1,165
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $335 |
| Teva Pharmaceuticals USA, Inc. | 2 | $249 |
| ABBVIE INC. | 7 | $228 |
| Otsuka America Pharmaceutical, Inc. | 2 | $141 |
| Janssen Pharmaceuticals, Inc | 2 | $73 |
| Vanda Pharmaceuticals Inc. | 2 | $66 |
| Alkermes, Inc. | 2 | $50 |
| Supernus Pharmaceuticals, Inc. | 1 | $23 |
Products named: CAPLYTA, VRAYLAR, REXULTI, UZEDY, AUSTEDO XR, SPRAVATO, HETLIOZ, ARISTADA.
Industry payments across CA — which companies pay providers there.
